Close Menu

organ transplant

The company filed its first suit against Natera in March, claiming the firm's kidney transplant test infringes patents underlying CareDx's AlloSure test.

CareDx claims that Natera is infringing on two of its patents related to non-invasive monitoring of organ transplant rejection through cell-free DNA analysis.

The company said its testing services revenues for the quarter rose nearly 120 percent year over year.

The firm's technology mimics infection in an in vitro setting in order to detect an immune response indicative of a latent infection. 

The company is currently conducting clinical studies to validate AlloSure's technology — which underlies its kidney transplant test — in lung transplant patients.

The investment bank said the company is strongly positioned as a leader in the transplant diagnostics market with tests that serve an unmet need.

The Toronto-based partners aim to create a rapid, multiplex test and companion point-of-care device for identifying lung transplant candidates.

A team led by researchers at the NHLBI are testing the efficacy of measuring ddcfDNA in blood as a biomarker of chronic rejection for lung transplants.

The company said 100 US transplant centers provided its AlloSure kidney transplant test to almost 3,400 patients in Q4.

The firm intends to use the proceeds for working capital, general corporate purposes and the potential repayment of indebtedness.

Pages